Table of Contents 
International Scholarly Research Notices
Volume 2015 (2015), Article ID 170236, 16 pages
http://dx.doi.org/10.1155/2015/170236
Research Article

Examining Provincial HPV Vaccination Schemes in Canada: Should We Standardise the Grade of Vaccination or the Number of Doses?

Carley Rogers1 and Robert J. Smith?2

1Department of Mathematics, The University of Ottawa, 585 King Edward Avenue, Ottawa, ON, Canada K1N 6N5
2Department of Mathematics and Faculty of Medicine, The University of Ottawa, 585 King Edward Avenue, Ottawa, ON, Canada K1N 6N5

Received 5 November 2014; Accepted 19 March 2015

Academic Editor: San-Lin You

Copyright © 2015 Carley Rogers and Robert J. Smith?. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Colucci, “HPV vaccination programs in Canada are we hitting the mark? Report card on cancer in Canada,” 2008.
  2. B. Y. Hernandez, L. R. Wilkens, X. Zhu et al., “Transmission of human papillomavirus in heterosexual couples,” Emerging Infectious Diseases, vol. 14, no. 6, pp. 888–894, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. K. Kjaer, K. Sigurdsson, O.-E. Iversen et al., “A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions,” Cancer Prevention Research, vol. 2, no. 10, pp. 868–878, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Llamazares and R. J. Smith?, “Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?” BMC Public Health, vol. 8, article 114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. National Advisory Committee on Immunization, Canada Communicable Disease Report Update of Human Papillomavirus Vaccines, vol. 38, (A-CS-1), 2012, http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php.
  6. S. J. Goldie, M. Kohli, D. Grima et al., “Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine,” Journal of the National Cancer Institute, vol. 96, no. 8, pp. 604–615, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. World Health Organization HPV Information Centre, “Human papillomavirus and related cancers in Canada,” Summary Report, 2010. View at Google Scholar
  8. B. Romanowski, “Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines,” Human Vaccines, vol. 7, no. 2, pp. 161–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Public Health Agency of Canada, Human Papillomavirus (HPV)—Sexual Health and STI—Public Health Agency of Canada, Public Health Agency of Canada (PHAC), Agence de la Sante Publique du Canada (ASPC), 2010, http://www.phac-aspc.gc.ca/std-mts/hpv-vph/fact-faits-eng.php.
  10. M. Lehtinen, J. Paavonen, C. M. Wheeler et al., “Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial,” The Lancet Oncology, vol. 13, no. 1, pp. 89–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. National Cancer Institute, Human Papillomavirus (HPV) Vaccines, NCI Fact Sheet, 2011, http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine.
  12. V. Brown and K. A. J. White, “The HPV vaccination strategy: could male vaccination have a significant impact?” Computational and Mathematical Methods in Medicine, vol. 11, no. 3, pp. 223–237, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  13. M. Brisson, N. Van De Velde, P. De Wals, and M.-C. Boily, “Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection,” Canadian Medical Association Journal, vol. 177, no. 5, pp. 464–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. V. Barnabas, P. Laukkanen, P. Koskela, O. Kontula, M. Lehtinen, and G. P. Garnett, “Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses,” PLoS Medicine, vol. 3, no. 5, pp. 624–632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Dobson, M. Dawar, D. Scheifele et al., “Are 2 doses of HPV vaccine adequate in girls?” in Proceedings of the 25th International Papilloma Conference, May 2009.
  16. B. D. Shearer, “HPV vaccinations: understanding the impact of HPV on disease,” Purple Paper 34, National Collaborating Centre for Infectious Diseases, 2011. View at Google Scholar
  17. M. Naus and G. Ogilvie, “Human papillomavirus vaccine program in BC: a good start with room for improvement,” British Columbia Medical Journal, vol. 52, no. 2, p. 95, 2010. View at Google Scholar · View at Scopus
  18. Government of Nova Scotia, School Immunization Schedule, 2012, http://novascotia.ca/dhw/cdpc/documents/13151_ChildhoodImmunizationSchedule_En.pdf.
  19. Toronto Public Health, 2008, http://www.toronto.ca/legdocs/mmis/2008/hl/decisions/2008-09-18-hl17-dd.pdf.
  20. Provincial Infectious Diseases Advisory Committee on Immunization, Recommendations for Human Papillomavirus Vaccination, Public Health Ontario, 2012, http://www.publichealthontario.ca/en/eRepository/PIDAC-I_Recommendations_for_HPV_vaccine_2012_Eng.pdf.
  21. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. R. Kreimer, P. González, H. A. Katki et al., “Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial,” The Lancet Oncology, vol. 12, no. 9, pp. 862–870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. The FUTURE II Study Group, “Quadrivalent vaccine against human papillomavirus to prevent high-grade cerivcal lesions,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1915–1927, 2007. View at Publisher · View at Google Scholar
  24. J. Paavonen, P. Naud, J. Salmeron et al., “Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, no. 9686, pp. 301–314, 2009. View at Publisher · View at Google Scholar
  25. M. Rotermann, “Trends in teen sexual behaviour and condom use,” Health Reports, vol. 19, no. 3, pp. 53–57, 2008. View at Google Scholar
  26. A. B. Moscicki, S. Shiboski, J. Broering et al., “The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women,” Journal of Pediatrics, vol. 132, no. 2, pp. 277–284, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. C. B. J. Woodman, S. Collins, H. Winter et al., “Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study,” The Lancet, vol. 357, no. 9271, pp. 1831–1836, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. M. Dobson, S. McNeil, M. Dionne et al., “Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial,” The Journal of the American Medical Association, vol. 309, no. 17, pp. 1793–1802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Doerfler, A. Bernhaus, A. Kottmel, C. Sam, D. Koelle, and E. A. Joura, “Human papilloma virus infection prior to coitarche,” American Journal of Obstetrics & Gynecology, vol. 200, no. 5, pp. 487.e1–487.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Muller and C. Bauch, “When do sexual partnerships need to be accounted for in transmission models of human papillomavirus?” International Journal of Environmental Research and Public Health, vol. 7, no. 2, pp. 635–650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Al-arydah and R. J. Smith?, “An age-structured model of human papillomavirus vaccination,” Mathematics and Computers in Simulation, vol. 82, no. 4, pp. 629–652, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  32. J. A. Brinkman, A. S. Caffrey, L. I. Muderspach, L. D. Roman, and W. M. Kast, “The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management,” European Journal of Gynaecological Oncology, vol. 26, no. 2, pp. 129–142, 2005. View at Google Scholar · View at Scopus
  33. A. Hildesheim, R. Herrero, S. Wacholder et al., “Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial,” Journal of the American Medical Association, vol. 298, no. 7, pp. 743–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. eMedicine, “Human Papillomavirus,” http://www.emedicine.com/med/topic1037.htm.
  35. M. Schiffman, P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder, “Human papillomavirus and cervical cancer,” The Lancet, vol. 370, no. 9590, pp. 890–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Heffernan, R. J. Smith, and L. M. Wahl, “Perspectives on the basic reproductive ratio,” Journal of the Royal Society Interface, vol. 2, no. 4, pp. 281–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. S. M. Blower and H. Dowlatabadi, “Sensitivity and uncertainty analysis of complex models of disease transmission: and HIV model: as an example,” International Statistical Review, vol. 62, no. 2, pp. 229–243, 1994. View at Publisher · View at Google Scholar
  38. J. P. Hughes, G. P. Garnett, and L. Koutsky, “The theoretical population-level impact of a prophylactic human papilloma virus vaccine,” Epidemiology, vol. 13, no. 6, pp. 631–639, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. B. Moscicki, “Impact of HPV infection in adolescent populations,” Journal of Adolescent Health, vol. 37, no. 6, pp. S3–S9, 2005. View at Publisher · View at Google Scholar · View at Scopus